Keith Kaplan is the CEO of TradeSmith

Review: TradeStops The Stock Genome Project

Table of Contents Just a Quick Intro Keith Kaplan and TradeSmith have started a new promo campaign for their TradeStops investment and portfolio-analysis software called the Stock Genome Project. Kaplan and his team have harnessed the power of their TradeStops software suite to offer “Wall Street caliber technology” to everyday investors. Based on a powerful … Read More

How the Delta Variant Fight Will Unleash a Wave of Genomics Innovation

Here we go again… Just when we thought the pandemic was over and it would be just a matter of time before life returned to normal, the delta variant comes along. We’re now in the middle of a third wave of COVID-19. With the seven-day average of reported infections running at more than 100,000 as … Read More

The #1 DNA Stock Leading the Genomic Revolution?

Precision medicine just took a HUGE step forward… CRISPR gene-editing technology was used on humans for the first time. Biotech company Intellia Therapeutics Inc. (Nasdaq: NTLA) achieved the milestone in a clinical trial in June. CRISPR editing was used to treat people with a rare protein disorder. Not only was the treatment safe, but preliminary … Read More

“Imperium” The Next Intel: The Microchip Company Powering the 199,000% DNA Mega Trend

Table of Contents: Who is Adam O’Dell What is “Imperium” technology Exploring the many applications of Imperium Technology The Microchip Company Powering the 199,000% DNA Mega Trend 3 Future DNA Titans Trading for as Little as $2 a Share Introducing Green Zone Fortunes How to Claim Everything Right Now “Amazing…” — Elon Musk, World’s Richest … Read More